pancreatic
No description yet: the sentence for this tag has not been written. 7 records carry it: 7 people.
Related tags
7 records
| Cancers | Other tags | ||||
|---|---|---|---|---|---|
Daniel D. Von Hoff Distinguished Professor, Translational Genomics Research Institute (TGen); Physician-in-Chief, HonorHealth Research Institute · Translational Genomics Research Institute (TGen) Led the MPACT trial of nab-paclitaxel plus gemcitabine and has run more first-in-human cancer trials than almost anyone. | Pancreatic ductal adenocarcinoma | none | early-phase, drug-development | ||
Hedy L. Kindler Professor of Medicine and Director of Gastrointestinal Oncology and Mesothelioma Programs, University of Chicago · University of Chicago Medicine Comprehensive Cancer Center Senior investigator of POLO and a leader in mesothelioma trials, including the ASCO guidelines for the disease. | Pancreatic ductal adenocarcinoma, Mesothelioma | none | mesothelioma, guidelines | ||
Marc G. Besselink Professor of Pancreatic and Hepatobiliary Surgery, Amsterdam UMC · Amsterdam UMC / Cancer Center Amsterdam Dutch surgeon who leads the PREOPANC trials testing chemotherapy or chemoradiation before pancreatic cancer surgery. | Pancreatic ductal adenocarcinoma | none | surgery, neoadjuvant | ||
Talia Golan Director, Pancreatic Cancer Center, Sheba Medical Center · Sheba Medical Center Led POLO, the first biomarker-driven trial in pancreatic cancer, which brought olaparib to BRCA carriers. | Pancreatic ductal adenocarcinoma | none | parp, brca | ||
Thierry Conroy Medical Oncologist, Institut de Cancérologie de Lorraine; Professor, University of Lorraine · Institut de Cancérologie de Lorraine Led the FOLFIRINOX trials that gave pancreatic cancer its most active chemotherapy in both metastatic and adjuvant settings. | Pancreatic ductal adenocarcinoma | none | chemotherapy, trialist | ||
Vinod P. Balachandran Surgical Oncologist and Member, Immuno-Oncology Service, Memorial Sloan Kettering Cancer Center · Memorial Sloan Kettering Cancer Center Surgeon-scientist whose personalised mRNA vaccine trial showed pancreatic cancer can provoke lasting T-cell immunity. | Pancreatic ductal adenocarcinoma | none | vaccine, immunotherapy | ||
Zev A. Wainberg Professor of Medicine and Co-Director, GI Oncology Program, UCLA Jonsson Comprehensive Cancer Center · UCLA Jonsson Comprehensive Cancer Center Led NAPOLI 3, the trial that made NALIRIFOX a first-line option for metastatic pancreatic cancer. | Pancreatic ductal adenocarcinoma, Gastric & gastro-oesophageal junction cancer | none | gastric, trialist |
